Vipin Garg, Altimmune CEO
June 24, 2024 07:13 AM EDTUpdated 09:17 AM
R&D

Al­tim­mune says ‘dou­ble G’ drug has even bet­ter lean mass preser­va­tion da­ta in obe­si­ty tri­al up­date

Katherine Lewin

News Reporter

OR­LAN­DO – Al­tim­mune is back with a full Phase 2 analy­sis of its “dou­ble G” drug pemvidu­tide, with the com­pa­ny tout­ing it is much bet­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times